TissueTinker develops a 3D bioprinted modeling platform that creates tissue-specific tumor organoids using proprietary bioactive hydrogels, enabling realistic replication of cancer growth and metastasis. This technology addresses the limitations of traditional preclinical testing methods by providing validated, high-throughput models that can utilize diverse patient-derived cells for more accurate therapeutic development.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional preclinical oncology testing methods often fail to accurately replicate the complexities of tumor growth and metastasis, leading to poor translation of drug candidates from preclinical studies to clinical trials. Current animal models present ethical concerns and often do not adequately represent human biology, resulting in wasted resources and delayed therapeutic development. Existing in vitro models lack the crucial physical and chemical factors of the tumor microenvironment.
Solution
TissueTinker offers a 3D bioprinted modeling platform that constructs tissue-specific tumor organoids using proprietary bioactive hydrogels, providing a more realistic and validated approach to preclinical oncology. These 3D tumor models replicate key aspects of cancer growth and metastasis, including the tumor microenvironment, enabling more accurate and predictive testing of novel therapeutics. The platform supports high-throughput analysis in 96-well plates and can be used with patient-derived cells and immortalized cell lines, democratizing preclinical testing and allowing for the development of new therapeutics for rare and underserved cancers. By replicating clinical results, TissueTinker aims to accelerate cancer therapeutic development, stepping away from guesswork and towards reproducible successes. The platform addresses the diversity gap in medical research by enabling testing on cells from patients of various backgrounds and health states.
Target Audience
TissueTinker's primary customers are pharmaceutical companies, biotech firms, and research institutions involved in preclinical drug development and cancer research.
Features
- Proprietary, tunable, and tissue-specific bioinks for creating a library of 3D tumor models
- 3D bioprinted tumor organoids that allow for more natural cell-to-cell signaling and growth compared to 2D cell cultures or animal models
- Replication of the tumor microenvironment, including physical and chemical aspects, for a more realistic representation of tumors
- High-throughput analysis in 96-well plates for rapid and reproducible results
- Compatibility with both patient cells and immortalized cell lines
- Validation against previous clinical results to demonstrate the platform's ability to replicate clinical data
- Development of curated sample panels for nanoparticles, mAbs, and small molecule drugs
- Expansion of the tumor model library through engineering tissue-specific bioinks